Y-BOX BINDING PROTEIN YB-1 IDENTIFIES HIGH-RISK PRIMARY BREAST CANCER PATIENTS BENEFITING FROM RAPIDLY CYCLED TANDEM HIGH-DOSE ADJUVANT CHEMOTHERAPY

被引：0
|
作者：
Gluz, O. [1 ]
Mengele, K.
Schmitt, M. [2 ]
Kates, R.
Diallo-Danebrock, R. [3 ]
Royer, H. [4 ]
Eckstein, N. [4 ]
Mohrmann, S. [3 ]
Nitz, U. [1 ]
Harbeck, N. [5 ]
机构：
[1] Breast Clin Niederrhein, W German Study Grp, Monchengladbach, Germany
[2] Tech Univ Munich, Clin Gynaecol & Obstet, Munich, Germany
[3] Univ Duesseldorf, Dusseldorf, Germany
[4] CAESAR, Bonn, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Frauenklin, D-8000 Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：55 / 55
页数：1
相关论文
共 50 条
  • [21] Y-box binding protein-1 (YB-1) inhibition triggers differentiation of normal and cancer stem cells from the brain
    Fotoyati, Abbas
    Abu-Ali, Sam
    Wang, Pei-Shan
    Deleyrolle, Loic
    Lee, Cathy
    Tricott, Joanna
    Chen, James
    Franciosi, Sonia
    Nakamura, Yas
    Sugita, Yasuo
    Uchiumi, Takeshi
    Kuwano, Michihiko
    Leavitt, Blair R.
    Singh, Sheila
    Jury, Alexa
    Jones, Chris
    Wakimoto, Hiroaki
    Reynolds, Brent A.
    Pallen, Catherine J.
    Dunn, Sandra E.
    CANCER RESEARCH, 2011, 71
  • [22] Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy
    Diallo-Danebrock, Raihanatou
    Ting, Evelyn
    Gluz, Oleg
    Herr, Alexander
    Mohrmann, Svjetlana
    Geddert, Helene
    Rody, Achim
    Schaefer, Karl-Ludwig
    Baldus, Stephan E.
    Hartmann, Arndt
    Wild, Peter J.
    Burson, Michael
    Gabbert, Helmut E.
    Nitz, Ulrike
    Poremba, Christopher
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 488 - 497
  • [23] Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer:: results of a multicentre phase III trial
    Nitz, UA
    Mohrmann, S
    Fischer, J
    Lindemann, W
    Berdel, WE
    Jackisch, C
    Werner, C
    Ziske, C
    Kirchner, H
    Metzner, B
    Souchon, R
    Ruffert, U
    Schütt, G
    Pollmanns, A
    Schmoll, HJ
    Middecke, C
    Baltzer, J
    Schrader, I
    Wiebringhaus, H
    Ko, Y
    Rösel, S
    Schwenzer, T
    Wernet, P
    Hinke, A
    Bender, HG
    Frick, M
    LANCET, 2005, 366 (9501): : 1935 - 1944
  • [24] Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: A longitudinal study
    Nieboer, P
    Buijs, C
    Rodenhuis, S
    Seynaeve, C
    Beex, LVAM
    van der Wall, E
    Richel, DJ
    Nooij, MA
    Voest, EE
    Hupperets, P
    Mulder, NH
    van der Graaf, WTA
    TenVergert, EM
    van Tinteren, H
    de Vries, EGE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) : 8296 - 8304
  • [25] High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer
    Ertz-Archambault, Natalie
    Northfelt, Donald W.
    Sonbol, Mohamad Bassam
    JAMA ONCOLOGY, 2020, 6 (08) : 1299 - 1300
  • [26] TMJ - A WELL-TOLERATED HIGH-DOSE REGIMEN FOR THE ADJUVANT CHEMOTHERAPY OF HIGH-RISK BREAST-CANCER
    RAZIS, ED
    SAMONIS, G
    COOK, P
    BEER, M
    MITTELMAN, A
    LAKE, DE
    FELDMAN, EJ
    PUCCIO, C
    AHMED, T
    JOURNAL OF MEDICINE, 1994, 25 (3-4) : 241 - 250
  • [27] Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer - A quality assessment study
    Svane, IM
    Homburg, KM
    Kamby, C
    Nielsen, DL
    Roer, O
    Sliffsgaard, D
    Johnsen, HE
    Hansen, SW
    ACTA ONCOLOGICA, 2002, 41 (7-8) : 675 - 683
  • [28] High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study
    Weiss, RB
    Rifkin, RM
    Stewart, FM
    Theriault, RL
    Williams, LA
    Herman, AA
    Beveridge, RA
    LANCET, 2000, 355 (9208): : 999 - 1003
  • [29] High-dose chemotherapy and hematopoietic stem cell rescue for metastatic and high-risk primary breast cancer
    Baynes, RD
    Klein, JL
    Dansey, RD
    Karanes, C
    Abella, E
    Akhtar, A
    Cassels, L
    Peters, WP
    BONE MARROW TRANSPLANTATION, 1998, 22 : S87 - S90
  • [30] Phase-III-trial of tandem high-dose chemotherapy vs. intensified conventional chemotherapy for patients with high-risk breast cancer
    Frick, M
    Mohrmann
    Eimermacher, H
    Kienast, J
    Ko, J
    Ziske, C
    Koch, O
    Kleinschmidt
    Fischer, J
    Fiebich, C
    Kirchner, H
    Ko, J
    Ostermann, H
    Nitz, U
    BONE MARROW TRANSPLANTATION, 1999, 23 : S18 - S18
12345